DRSLTR


				Goodwin Procter LLP 601 Marshall St.
				Redwood City, CA 94063 goodwinlaw.com
				+1 650 752 3100

March 14, 2025

CONFIDENTIAL SUBMISSION VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, D.C. 20549

Re:	Nektar Therapeutics

Draft Registration Statement on Form S-3

Ladies and Gentlemen:

On behalf of Nektar Therapeutics (the “Company”), we are confidentially submitting a draft Registration Statement on Form S-3 (the “Registration Statement”) to the staff of the Securities and Exchange Commission for confidential non-public review. The Registration Statement submitted herewith relates to (i) the Company’s shelf registration statement for the sale of the Company’s securities in one or more offerings and (ii) the Company’s proposed offering of shares of its common stock through at-the-market offerings.

The Company undertakes to publicly file the Registration Statement and non-public draft submissions at least two business days prior to the requested effective time and date of the Registration Statement.

If you have any questions regarding this filing, please contact Justin Platt at (212) 459-7340.

Best regards,

/s/ Justin Platt

Justin Platt

Goodwin Procter LLP